Orthofix International

Orthofix Medical, Inc. engages in the provision of medical devices. It operates through the following business segments: Global Spine and Global Extremities. The Global Spine reporting segment offers three primary product categories: Bone Growth Therapies, Spinal Implants, and Biologics. The Bone Growth Therapies product category manufactures, distributes, and provides support services of bone growth stimulator devices that enhance bone fusion. The Spinal Implants product category designs, develops, and markets a broad portfolio of motion preservation and fixation implant products used in surgical procedures of the spine. The Biologics product category provides a portfolio of regenerative products and tissue forms that allow physicians to treat a variety of spinal and orthopedic conditions. The Global Extremities reporting segment offers products and solutions that allow physicians to successfully treat a variety of orthopedic conditions unrelated to the spine. The company was founded on October 19, 1987 and is headquartered in Lewisville, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Orthofix and SeaSpine post mixed Q4 results, eye synergies and growth

SeaSpine and Orthofix reported mixed Q4 performances but demonstrated overall revenue growth for the full year, with positive revenue guidance for 2023.
The merger synergies and product demand strengths are key highlights, while challenges in profitability and regulatory hurdles in Europe require attention.
Opportunities lie in integration efforts, cost efficiencies, and exploring new markets, indicating a strategic growth trajectory for the combined entity.
The upcoming Analyst Teach-In event and focus on operational planning underscore the commitment to transparency and strategic alignment post-merger.

Orthofix reports robust Q1 earnings, raises full-year revenue guidance

Orthofix International's Q1 2023 earnings call highlighted strong financial performance, strategic initiatives, and raised revenue guidance, underscoring growth prospects.
The company's focus on operational efficiency, product categories, and profitability signals a resilient business strategy amidst market challenges and competitive landscape.
With a robust financial foundation, Orthofix is well-positioned to navigate challenges, capitalize on growth opportunities, and drive sustainable value creation for shareholders.

Orthofix International reports robust Q2 earnings and growth outlook

Orthofix International delivered a strong Q2 performance, with notable revenue growth and positive outlook for 2023.
Efforts to integrate merged businesses are yielding results, with a focus on revenue enhancement and operational streamlining.
Challenges such as cash flow and supply chain disruptions are being addressed through strategic investments and operational improvements.
The company's focus on growth, efficiency, and strategic partnerships positions it well for future success and value creation.

Orthofix reports robust Q3 revenue growth, eyes profitability and stability

Orthofix International demonstrated strong revenue growth and market performance in Q3 2023, driven by successful product lines and strategic initiatives.
While facing challenges such as cash flow outflows and margin adjustments, the company remains focused on profitability and financial stability.
Opportunities lie in sustaining positive momentum, achieving cash flow positivity in 2024, and leveraging growth prospects through product innovation and market expansion.

Orthofix reports robust Q4 earnings, eyes growth in key segments

Orthofix International's Q4 2023 earnings call highlighted strong financial performance, strategic initiatives, and growth in key segments.
The company's focus on market share, distributor relationships, and portfolio enhancements positions it well for future success.
Despite challenges in a competitive landscape, Orthofix remains optimistic about growth opportunities and aims for continued innovation and collaboration.

Orthofix International reports robust Q1 earnings and raises 2024 guidance

Orthofix International (OFIX) delivered a strong Q1 2024 performance, focusing on growth, innovation, and operational efficiency. The company showcased revenue growth, margin expansion, and strategic priorities for the year. Challenges include sustaining growth in competitive markets and optimizing operational aspects, while opportunities lie in leveraging technology and talent for further growth.

Orthofix International reports strong Q2 performance and outlines growth strategies

Orthofix International's Q2 performance reflects solid revenue growth and margin expansion, supported by new product releases and operational efficiency.
While facing challenges in cash flow optimization, the company's strategic focus on innovation and synergies positions it well for future growth.
Opportunities in technology investment, cross-selling, and distribution enhancements offer avenues for Orthofix International to drive sustained growth and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced that President and Chief Executive Officer Jon Serbousek and Chief Financial Officer Doug Rice will participate in a fireside chat during the upcoming Stifel 2022 Healthcare investor conference on Wednesday, November 16, 2022 at 8:00 a.m.

Orthofix Medical Announces Participation in Upcoming Stifel Healthcare Conference

Orthofix Medical, Inc. (NASDAQ:OFIX ) Q3 2022 Earnings Conference Call November 3, 2022 8:30 AM ET Company Participants Alexa Huerta - Senior Director, IR Jon Serbousek - President, CEO & Director Douglas Rice - CFO & CAO Conference Call Participants David Turkaly - JMP Securities Mathew Blackman - Stifel, Nicolaus & Company Jeffrey Cohen - Ladenburg Thalmann & Co. James Sidoti - Sidoti & Company Operator Good morning. My name is Gavin and I will be your conference operator today.

Orthofix Medical, Inc. (OFIX) Q3 2022 Earnings Call Transcript

Orthofix (OFIX) delivered earnings and revenue surprises of 550% and 2.70%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Orthofix (OFIX) Q3 Earnings and Revenues Surpass Estimates

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX) today reported its financial results for the quarter ended September 30, 2022.

Orthofix Reports Third Quarter 2022 Results

First Eagle Alternative Capital BDC Inc

SeaSpine Holdings

NEW YORK , Nov. 2, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: First Eagle Alternative Capital BDC, Inc. (NASDAQ: FCRD)'s  sale to Crescent Capital BDC, Inc. If you are a First Eagle shareholder, click here to learn more about your rights and options . SeaSpine Holdings Corporation (NASDAQ: SPNE)'s  sale to Orthofix Medical Inc. for 0.4163 shares of Orthofix common stock for each share of SeaSpine common stock.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FCRD, SPNE, OFIX

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced that it will release its third quarter 2022 financial results before market open on Thursday, November 3, 2022.

Orthofix Medical Schedules Third Quarter Earnings Release and Conference Call for November 3, 2022

NEW YORK , Oct. 14, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Orthofix Medical Inc. ("Orthofix" or the "Company") (NASDAQ: OFIX) in connection with the proposed acquisition of the Company by SeaSpine Holdings Corporation ("SeaSpine") (NASDAQ: SPNE).  Under the terms of the merger agreement, the Company's shareholders will receive 0.4163 shares of SeaSpine common stock for each Orthofix share owned, representing implied per-share merger consideration of approximately $2.44 based upon SeaSpine' October 13, 2022 closing price of $5.86.

SHAREHOLDER ALERT: Weiss Law Investigates Orthofix Medical Inc.

Orthofix (OFIX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Orthofix (OFIX) Soars 5%: Is Further Upside Left in the Stock?

LEWISVILLE, Texas--(BUSINESS WIRE)--Full market release and first implants of Legacy Demineralized Bone Matrix, a putty for filling voids or gaps in boney defects

Orthofix Announces First Patient Implants with Legacy Demineralized Bone Matrix for Spine, Pelvic and Extremities Procedures

LEWISVILLE, Texas--(BUSINESS WIRE)--Virtuos™ Lyograft receives the 2022 Spine Technology Award from Orthopedics This Week, the most widely read publication in the Orthopedics industry

Orthofix and MTF Biologics Recognized with 2022 Spine Technology Award for Virtuos Lyograft – a First-of-Its-Kind, Shelf-Stable and Complete Autograft Substitute for Spine and Orthopedic Procedures

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Orthofix Medical Inc. (NASDAQ: OFIX) and SeaSpine Holdings Corporation is fair to Orthofix shareholders. Following the close of the transaction, Orthofix shareholders will own approximately 56.5% of the combined company. Halper Sadeh encourages Orthofix shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763

OFIX STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Merger of Orthofix Medical Inc. Is Fair to Shareholders

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX) today announced preliminary unaudited third quarter 2022 net sales of approximately $114 million, an increase of 1% on a reported basis and 5% on a constant currency basis versus the prior year. For the nine months ended September 30, 2022, preliminary unaudited net sales were approximately $339 million, which was flat to prior year on a reported basis and an increase of 2% on a constant currency basis. “We are very excited

Orthofix Announces Preliminary Third Quarter and Year-To-Date 2022 Net Sales Results

LEWISVILLE, Texas & CARLSBAD, Calif.--(BUSINESS WIRE)--Orthofix (NASDAQ: OFIX), a global medical device company with a spine and orthopedics focus, and SeaSpine (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced they have entered into a definitive agreement to combine in an all-stock merger of equals. The combined company, to be named prior to the transaction's closing, will be a leading global spine and ortho

Orthofix and SeaSpine to Combine in Merger of Equals to Create Leading Global Spine and Orthopedics Company

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced the presentation of long-term evidence highlighting the clinical management of cervical disc arthroplasty during the North American Spine Society (NASS) 2022 annual meeting October 12-15 in Chicago. “We are pleased to sponsor the presentation of data supporting the clinical effectiveness of cervical disc arthroplasty including five-year dat

Orthofix Announces Presentation of Long-Term Evidence Highlighting the Clinical Management of Cervical Disc Arthroplasty at North American Spine Society Annual Meeting

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced that President and Chief Executive Officer Jon Serbousek and Chief Financial Officer Doug Rice will be presenting during the upcoming Sidoti Virtual Investor Conference on Wednesday, September 21, 2022 at 10:00 a.m. ET. The conference will be held in a virtual format, and one-on-one meetings will also be held throughout the day. A live webc

Orthofix Medical Announces Participation in Upcoming Sidoti Virtual Investor Conference

Orthofix Medical Inc. (NASDAQ:OFIX ) Q2 2022 Earnings Conference Call August 5, 2022 8:30 AM ET Company Participants Alexa Huerta – Senior Director-Investor Relations Jon Serbousek – President and Chief Executive Officer Doug Rice – Chief Financial Officer Conference Call Participants Mathew Blackman – Stifel Jeffrey Cohen – Ladenburg Jim Sidoti – Sidoti and Company Operator Hello, and a warm welcome to Orthofix Medical's Q2 2022 Earnings Call. My name is Melissa, and I'll be your operator today.

Orthofix Medical Inc.'s (OFIX) CEO Jon Serbousek on Q2 2022 Results - Earnings Call Transcript

Orthofix (OFIX) delivered earnings and revenue surprises of 14.29% and 0.57%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Orthofix (OFIX) Beats Q2 Earnings and Revenue Estimates

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX) today reported its financial results for the quarter ended June 30, 2022. Net sales were $118.1 million, earnings per share (“EPS”) was $0.12, and adjusted EPS was $0.08. “We're pleased with our execution in the second quarter, which was led by double digit growth in our global orthopedic business as well as early commercial traction of new spine products. In addition, we made significant progress on our innovation initiati

Orthofix Reports Second Quarter 2022 Results

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced a strategic partnership agreement with CGBio, a developer of innovative, synthetic bone grafts currently used clinically in Asia for spine, orthopedic, trauma and dental applications. The two companies will work together for clinical development and commercialization of Novosis™ recombinant human bone morphogenetic protein-2 (rhBMP-2) bone

Orthofix Medical and CGBio Announce Strategic Partnership Agreement for Novosis rhBMP-2 Bone Graft Solutions

Orthofix (OFIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Orthofix (OFIX) to Report a Decline in Earnings: What to Look Out for

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced that it will release its second quarter 2022 financial results before market open on Friday, August 5, 2022. Jon Serbousek, President and Chief Executive Officer, and Doug Rice, Chief Financial Officer, will host a conference call and webcast to review the Company's results at 8:30 a.m. ET the same day. Interested parties may access the con

Orthofix Medical Schedules Second Quarter Earnings Release and Conference Call for August 5, 2022

LEWISVILLE, TEXAS--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced the limited market release and first patient implant of the Virtuos™ Lyograft, a first-of-its-kind, shelf-stable and complete autograft substitute for spine and orthopedic procedures. This allograft is prepared by MTF Biologics through a proprietary process that preserves all biologic components necessary for bone healing within the graft.

Orthofix Announces First Clinical Use of Virtuos Lyograft – a First-of-Its-Kind, Shelf-Stable and Complete Autograft Substitute for Spine and Orthopedic Procedures

LEWISVILLE, Texas--(BUSINESS WIRE)--New partnership combines the Orthofix Fitbone™ system with LimaCorporate's 3D-printed pelvic fixation device for patients with high hip dislocation.

Orthofix Medical and LimaCorporate Announce Partnership to Provide Solution for Patients with High Hip Dislocation for the US Market

LEWISVILLE, Texas--(BUSINESS WIRE)--Five year data shows M6-C patients continue to have significant benefits in neck disability and shoulder/arm pain scores compared to ACDF patients.

Orthofix M6-C Artificial Cervical Disc IDE Study Data to be Presented at ISASS Demonstrates Continued Statistically Significant Benefits at Five Years

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced that President and Chief Executive Officer Jon Serbousek and Chief Financial Officer Doug Rice will participate in the upcoming UBS Global Healthcare investor conference. Mr. Serbousek will be presenting on Monday, May 23, 2022 at 2:45 p.m. ET. The conference will be held live at the Lotte New York Palace in New York, NY. The presentation w

News for Orthofix International Stock (OFIX)